Soft Tissue Sarcoma Market
Report ID: SQMIG35I2479
Report ID: SQMIG35I2479
sales@skyquestt.com
USA +1 351-333-4748
Report ID:
SQMIG35I2479 |
Region:
Global |
Published Date: January, 2026
Pages:
188
|Tables:
92
|Figures:
71
Global Soft Tissue Sarcoma Market size was valued at USD 4.11 Billion in 2024 and is poised to grow from USD 4.45 Billion in 2025 to USD 8.36 Billion by 2033, growing at a CAGR of 8.2% during the forecast period (2026–2033).
The market is growing quickly due to the increasing prevalence of cancer worldwide, greater awareness surrounding rare oncological diseases, and a strong pipeline of targeted therapies. The changing landscape of diagnostics, with MRI and PET scans, allows for better and quicker early detections, leading to early and better treatment options. As large pharmaceutical companies are investing in new drugs, like tyrosine kinase inhibitors and immunotherapies, the market is growing. The development of innovative stages of pharmaceuticals have also been supported, by providing faster approvals (the FDA) and orphan drug designations (or traded as "Orphan Drug"), which previously indicated advisers for drugs meant for small populations, to adopt or develop new treatment modalities.
Nonetheless, the market is restricted by the limited patient population, high cost of treatment, and the difficulty of diagnosing soft tissue sarcoma in an early and accurate fashion. Given the heterogeneity of soft tissue sarcomas, conducting clinical trials for them is also quite difficult, meaning that patients can often be treated late or treated incorrectly. Side effects associated with chemotherapy and radiation therapy can preclude patients from adhering to treatment regimens. In developing regions, limited access to a specialized healthcare infrastructure and limited access to oncology expertise also limits market penetration in those areas.
How are Emerging Technologies like AI and IOT Transforming the Soft Tissue Sarcoma Market?
Artificial intelligence (AI) and the Internet of Things (IoT) are transforming the way soft tissue sarcoma (STS) is diagnosed, monitored, and treated. They include high-resolution radiomics-based imaging, AI-driven and deep-learning models that can now outperform traditional models in detecting and classifying STS subtypes. AI model applied to CT scans of STS, achieved an accuracy of retroperitoneal sarcomas grade (G2, G3) more accurately than non-augmented imagery could, allowing for more timely and tailored treatment. Deep-learning models trained on histopathology slides improved the accuracy of the pathologist when analysing histopathology slides trained on histopathology slides proved to be resulting in fewer delays, improved subtype classification and the ability to avoid overtreatment for low-risk patients with STS.
In April 2025, researchers led by Adam Thiesen introduced a revolutionary AI-driven model that classifies pediatric soft tissue sarcoma subtypes using standard digitized H&E pathology slides. The algorithms were trained on images across nine subtypes, generating remarkable accuracy, including ability to clearly distinguish Ewing sarcoma from other types. This process replicates an expert pathologist's performance, is low enough for a standard laptop, and offers rapid, accurate, and timely diagnostics that can be used even in resource-limited areas.
Market snapshot - 2026-2033
Global Market Size
USD 3.19 Billion
Largest Segment
Angiosarcoma
Fastest Growth
Others
Growth Rate
7.67% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global Soft Tissue Sarcoma Market is segmented by Type, Diagnosis, Treatment, End User and region. Based on Type, the market is segmented into Angiosarcoma, Epithelioid Sarcoma, Gastrointestinal Stromal Tumor (GIST) and Others. Based on Diagnosis, the market is segmented into Biopsy, Ultrasound Scan, Magnetic Resonance Imaging (MRI) and Others. Based on Treatment, the market is segmented into Targeted Therapy, Chemotherapy, Anti-Angiogenesis Drugs, Radiation Therapy and Surgery. Based on End User, the market is segmented into Hospitals and Clinics, Cancer Research Centers and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Based on the global soft tissue sarcoma market forecast, the angiosarcoma section has the dominant position in the market due to the aggressive clinical nature of this disease requiring prompt and multi-modal treatment. This neoplasm involves the lining of blood vessels, has relatively high recurrence and metastasis rates and recent advancements in immunotherapy and targeted therapy specific to vascular tumors have improved treatment response, which reinforces angiosarcoma's lead based on soft tissue sarcoma type.
The gastrointestinal stromal tumor (GIST) segment is projected to witness the fastest growth due to excellent responsiveness to tyrosine kinase inhibitors such as imatinib and sunitinib. The rising awareness of GISTs, increasing rates of genetic testing, and regular screening of gastrointestinal tumors have significantly improved rates of diagnose for patients suffering from GISTs.
The diagnosis sub-segment currently dominates the market. A diagnosis of soft tissue sarcomas is imperative as they have a variety of subtypes and unpredictable behavior. Developments in advanced imaging such as MRI and PET scans, and improved histopathological and molecular diagnosis, have improved the diagnostic investigation. As patients become more stepped up in awareness of diagnosis and new technologies are introduced to biopsy and advanced imaging, this sub-segment will continue to dominate.
The treatment sub-segment is developing as the fastest growing segment, as personalized medicine is scaling rapidly with its use and immunotherapy is expanding its reach. With biologics and combination therapies entering the marketplace, the treatment sub-segment is likely to grow quickly, aided by increasing access to specialized oncology centers and individualized approaches for patients.
To get detailed segments analysis, Request a Free Sample Report
As per the global soft tissue sarcoma market analysis, The North America market is by far leading the global market due to advanced healthcare systems, new therapies being quickly adopted, and public awareness of rare cancers. The high level of research infrastructure are for further illumination in the leadership role of this market. Likewise, high health-expenditure rates, and collaboration between health organizations and research institutions have allowed for continuing investment and exploration of diagnosis.
The U.S. is the top provider in North America, with advanced molecular diagnostics as well as the greatest number of open clinical trials for STS. U.S. cancer centers offer the best immediate access to targeted therapies and combination therapy. The centers also worked together to fast-track a new sarcoma therapy with the specific goal of improving survival rates. Multi-modal treatment pathways utilizing surgery, like angiosarcoma, ultimately supporting the strength and endurance of the U.S. market.
Canada is the fastest-growing country in North America with rising investment in oncology as well as increased adoption of diagnostic technologies like MRI and biopsy guided molecular testing. The initiatives in public health related to rarer cancers like soft tissue sarcoma, as well as better access to patients for personal medicine are coming together. The expansion, along with better knowledge and more funding from government support will help Canada's role in the soft tissue sarcoma growth market.
Europe is recognized as the region with the most growth in the global STS market due to structured cancer control plans and existing integration of precision medicine into national health systems. The transfer of knowledge through cross-border research collaboration and increased government support in orphan drugs approvals and digital pathology tools increase diagnostic speed and accuracy. Expanded public-private partnerships are developing a vibrant ecosystem for more effectively advancing soft tissue sarcoma treatment throughout the region.
Germany's established and solid healthcare system as well as its early adoption of high-quality imaging and biopsy protocols result in it having the leading European market position. The advancement of integrating radiomics into the assessment of sarcoma is another example of how the diagnostic work-up in Germany has become more comprehensive, diverse, and effective. The insurance system in Germany also provides access to surgeries and systemic treatment via specialist care.
France is experiencing a rapid uptake in the soft tissue sarcoma market due to increased attention on rare cancers and access to centralized treatment networks. The biobanks of sarcoma resources have expanded, enabling better genetic profiling to facilitate precision medicine. The French government-supported initiatives aimed to decrease the cancer divide, as well as implement AI in diagnostics workflow, positioned France as a rising force in soft tissue sarcoma care throughout Europe.
In the U.K., there is continued good delivery via both national initiatives to improve early detection and the existence of specialist sarcoma units in the NHS. U.K. adoption of AI-assisted pathology and alignment with standard protocols are likely to improve the accuracy of subtype assignment. Continued financial investment into personalized oncology and participation in clinical trials, including basket trials into personalized oncology activities, is certainly deepening its potential contribution to the growth of the European soft-tissue sarcoma market.
Asia Pacific has become a growth region driven by rising cancer prevalence, evolving healthcare systems, and the increased adoption of personalized medicine. Opportunities to foster better early diagnosis, through methodologies such as AI-integrated imaging and genomic testing, are developing in both Japan and South Korea. Clinical partnerships with global collaborators are leading to greater integration of sarcoma from available standard treatment regimens and contributing to the growing footprint of the region in the sarcoma market.
Japan leads the Asia Pacific market for several reasons, including its sophisticated oncology ecosystem and the fact that genetic testing is widely used in diagnosing sarcoma. Research related to sarcoma treatment and care featured both the integration of wearable monitoring and SMCT post-treatment care to improve relapse detection in STS patients. Japan's focus on evidence-based technological integration will ensure Asia Pacific maintains its region's primary status for managing and treating soft tissue sarcoma.
South Korea is the fastest developing market due to government's strong support of digital health innovation and rare disease management is driving that growth. They are now using AI-supported biopsy analysis for sarcoma classification, which is positive for practicing pathologists and ultimately lowering the burden of diagnosing sarcomas in regional hospitals. With robust clinical research collaborations, South Korea's established digital health innovation will put them firmly on the international map for soft tissue sarcoma.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Increasing Incidence and Prevalence of Soft Tissue Sarcoma
Advancements in Diagnostic and Therapeutic Approaches
Rarity and Heterogeneity of Soft Tissue Sarcoma
High Cost of Novel Therapies and Limited Reimbursement
Request Free Customization of this report to help us to meet your business objectives.
The global soft tissue sarcoma market outlook is highly competitive, large biopharma companies including Roche, Bristol‑Myers Squibb, Novartis, and Pfizer are key players in the late-stage STS therapy market also including tyrosine kinase inhibitors, immunotherapies, and anti‑angiogenics. Companies are demonstrating competitive differentiation through strategic trial networks, precision oncology partnerships, and regulatory accelerations. These resulting innovations indicate a transition to multi‑modal and personalized treatment protocols as competitive tools.
As per the global soft tissue sarcoma industry analysis, the startup scene is rapidly evolving, driven by advances in AI, IoT, and data analytics. A number of these start-ups are using AI enabled platforms to optimize drug discovery and improve diagnostic accuracy. All these start-ups tend to focus on niche areas like immunotherapy and gene editing, to solve expected clinical needs. Most of their lean models and disruptive technologies potentially allows them to be a player in a space dominated to date by the larger players.
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, the global soft tissue sarcoma industry is experiencing robust growth driven by advances in AI and IoT, and the evolution of diagnostics and personalized therapies. AI-enabled tools enable early detection and precision medicine, while IoT-enabled efficiency, remote patient monitoring, and data-driven algorithm development also improve real-time monitoring of patients. However, factors such as rising treatment costs, geographic-disparities and limited awareness and education on the development of the treatment of digital diagnostics for cancer in developing countries, and regulatory approvals that will further impact market growth negatively.
Despite these restraints, technological developments and collaborations between established and startup firms are likely to help overcome barriers. The ongoing integration of AI and IoT will keep optimizing therapeutic outcomes for treatment while ensuring better access and more streamlined approaches. The growth of the market opportunity will shift how the market operates.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 4.11 Billion |
| Market size value in 2033 | USD 8.36 Billion |
| Growth Rate | 8.2% |
| Base year | 2024 |
| Forecast period | 2026-2033 |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Soft Tissue Sarcoma Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Soft Tissue Sarcoma Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Soft Tissue Sarcoma Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Soft Tissue Sarcoma Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
